Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…
HOME > COMMENTARY
COMMENTARY
- Why Eisai's Novel Anticancer Agent Halaven Received the Highest Ever Operating Profit Rate
August 8, 2011
- Current Promising Drug Candidates with a New Mode of Action
August 8, 2011
- Consumption Tax Hike to Go With Measures to Increase Efficiency of Soc. Security System
July 18, 2011
- Actos Bladder Cancer Risk Highlights Problems with Safety Measures in Japan
July 4, 2011
- Era of Competition Dawns in Market for AD Treatments
June 27, 2011
- Will Dialogue between PSJ, JAMS Accelerate Development of Switch OTC Drugs?
June 20, 2011
- Return to Full-bore Growth Strategy Risky for Taiyo Pharm
June 13, 2011
- Why the Same Mistake Repeated? -MSD's Promotion Code Violations
June 6, 2011
- GE Makers to Make Difficult Decision on Actos Generics due to Combination Patent
June 6, 2011
- Effects of Changes to Accelerate Approval to Be Seen from November
May 30, 2011
- Japan's Most Admired Pharma Companies in 2010
April 4, 2011
- Will New Disclosure GL Promote Industry-Academia Alliances?
March 28, 2011
- Use of Generics by Welfare Recipients
March 7, 2011
- Wholesalers' Profits Drop Sharply Putting Premium for New Drug Development in Peril
February 21, 2011
- Safety Measures Based on Common Medical Knowledge Questioned by Court: Iressa Affair
February 21, 2011
- Recent Topics in Promising Anticancer Therapeutics
January 17, 2011
- Development Race for Oral Anticoagulants Entering Final Stretch
October 11, 2010
- How to Eliminate Concerns about Safety of Liovel
October 4, 2010
- Will It Be Possible to Eliminate Unnecessary Equivalence Studies for Generics?
September 20, 2010
- Big Pharma Losing Flagships within a Few Years and Shifting Paradigm
September 13, 2010
ページ
With Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) hogging the headlines for its biggest-ever price tag in Japan, many continue to perceive high-price medicines as the main culprit of strained health finances, contending that they are driving up drug spending. But, is…
The workforce in the Japanese pharmaceutical sector is getting leaner and leaner, with the latest securities reports filed by 27 drug makers showing a 1.3% fall in their headcounts in FY2018, or 888 employees. The downtrend has been continuing since…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…